Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients

NCT06382571 | Completed FDA Drug

• 1 other identifier: 026/66
• Study Type: observational
• Target: 396
• Locations: 0 countries
• Sites: N/A

Brief Summary

Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs). Methods: The retrospective cohort study was designed to collect data on Thai heart failure with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine their association with the sub-target group.

Conditions

Heart Failure With Reduced Ejection Fraction

Outcome Measures

Primary Outcomes (1)

• factors associated with sub - target dose of ACEIs,ARBs,ARNI

  factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).

  12 months

Study Arms (2)

Sub - target dose group

Patients who received sub - target dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).

Drug: Renin-Angiotensin System Inhibitor

Target dose group

Patients who received target dose or maximal tolerated dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs)

Drug: Renin-Angiotensin System Inhibitor

Interventions

Renin-Angiotensin System Inhibitor DRUG

Sub - target dose group; Target dose group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult out - patients who were first diagnosed be heart failure with left vetricular ejection fraction less than 40% and recieved one of ACEIs,ARBs,ARNI drugs.

You may qualify if:

• Patients who were first diagnosed be heart failure with left ventricular ejection fraction less than 40%.
• Received one of ACEIs,ARBs,ARNI drugs.

You may not qualify if:

• Electronic medical records was not complete enough to analyse.
• Patients who had history of heart transplantation or had heart transplantation plan in last 12 months.

Sponsors & Collaborators

• Chulalongkorn University: lead

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 20, 2024
• First Posted: April 24, 2024
• Study Start: January 1, 2016
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2021
• Last Updated: April 24, 2024

Record last verified: 2024-02